$ABBV
AbbVie Inc. · NYSE · Healthcare
- Market cap
- 504.76B
- Volume
- 4.60M
- P/E
- 80.69
- Day range
- 282.30 – 286.76
- 52w range
- 190.75 – 291.40
- Analyst target
- 284.96
AI Summary
Generating a unique summary for ABBV…
AI-generated for information only — not investment advice.
Share this ticker
$ABBV +0.16% at 285.64 David Tepper and 0 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/ABBV
Company summary
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Institutional ownership
Institutions hold 77.36% · insiders 0.11% · 5,277 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 149.49M | $42.70B | 8.46% | 2026-06-30 |
| Vanguard Capital Management LLC | 115.40M | $32.96B | 6.53% | 2026-06-30 |
| State Street Corporation | 82.60M | $23.59B | 4.67% | 2026-06-30 |
| Vanguard Portfolio Management LLC | 48.48M | $13.85B | 2.74% | 2026-06-30 |
| JPMORGAN CHASE & CO | 47.86M | $13.67B | 2.71% | 2026-06-30 |
| Geode Capital Management, LLC | 47.00M | $13.42B | 2.66% | 2026-06-30 |
| Morgan Stanley | 38.90M | $11.11B | 2.20% | 2026-06-30 |
| Capital Research Global Investors | 30.10M | $8.60B | 1.70% | 2026-06-30 |
| NORGES BANK | 25.55M | $7.30B | 1.45% | 2026-06-30 |
| Bank of America Corporation | 21.24M | $6.07B | 1.20% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| DONOGHOE NICHOLAS | Officer | Sale at price 250.00 per share. | 32.7K | 2026-08-14 |
| DONOGHOE NICHOLAS | Officer | Conversion of Exercise of derivative security at price 79.02 per share. | 32.7K | 2026-08-14 |
| MEYER MELODY B | Director | Stock Award(Grant) at price 0.00 per share. | 1.1K | 2026-05-08 |
| RAPP EDWARD J | Director | Stock Award(Grant) at price 0.00 per share. | 1.1K | 2026-05-08 |
| HART BRETT J | Director | Stock Award(Grant) at price 0.00 per share. | 1.1K | 2026-05-08 |
| BURNSIDE WILLIAM H L | Director | Stock Award(Grant) at price 0.00 per share. | 1.1K | 2026-05-08 |
| AUSTIN ROXANNE SCHUH | Director | Stock Award(Grant) at price 0.00 per share. | 1.1K | 2026-05-08 |
| WADDELL FREDERICK H | Director | Stock Award(Grant) at price 0.00 per share. | 1.1K | 2026-05-08 |
| FREYMAN THOMAS C | Director | Stock Award(Grant) at price 0.00 per share. | 1.1K | 2026-05-08 |
| FALK THOMAS J | Director | Stock Award(Grant) at price 0.00 per share. | 1.1K | 2026-05-08 |
| ROBERTS REBECCA B. | Director | Stock Award(Grant) at price 0.00 per share. | 1.1K | 2026-05-08 |
| DAVIS JENNIFER L | Director | Stock Award(Grant) at price 0.00 per share. | 1.1K | 2026-05-08 |
Analyst ratings
Consensus score 1.70 (1 = strong buy, 5 = sell) · mean target 284.96
- Goldman SachsNeutralmain2026-10-23
- BarclaysOverweightmain2026-10-21
- RBC CapitalOutperformreit2026-10-13
- UBSNeutralmain2026-10-09
- GuggenheimBuyreit2026-10-09
- JP MorganOverweightmain2026-10-08
- Cantor FitzgeraldOverweightmain2026-10-08
- Morgan StanleyOverweightmain2026-10-07
- ScotiabankSector Outperformmain2026-10-06
- HSBCBuymain2026-09-10
Earnings
Next report: 2026-10-30
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | 1.86 | 1.78 | 0.08 |
| 4Q2025 | 2.71 | 2.65 | 0.06 |
| 1Q2026 | 2.65 | 2.67 | -0.02 |
| 2Q2026 | 3.65 | 3.61 | 0.04 |
SEC filings
- 8-KCorporate Changes & Voting Matters2026-10-15Open
- 8-KCorporate Changes & Voting Matters2026-10-05Open
- 8-KCorporate Changes & Voting Matters2026-09-03Open
- 8-KCorporate Changes & Voting Matters2026-08-18Open
- 10-QPeriodic Financial Reports2026-08-03Open
- 8-KCorporate Changes & Voting Matters2026-07-31Open
- 8-KCorporate Changes & Voting Matters2026-07-06Open
- 11-KAnnual report of employee stock purchase2026-06-24Open
- 8-KCorporate Changes & Voting Matters2026-06-22Open
- SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-06-01Open
Latest ABBV news
- AbbVie Won FDA Approval for At-Home Skyrizi Starts in Crohn’s. Here’s When It Should Show Up in Sales
Key Stats for AbbVie StockCurrent Price: $285. 64Target Price (Mid): ~$364Street Target: ~$285Potential Total Return: ~27%Annualized IRR: ~6% / year__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__ >>> What Happened?AbbVie (ABBV) now lets Crohn’s patients start Skyrizi at home, and when that reaches sales depends on how fast insurers move.
Sat, 24 Oct 2026 20:24:25 +0000
- AbbVie (ABBV) Stock Gets Fair Value Bump After Analyst Target Increases
AbbVie’s analyst narrative has shifted again, with fair value in one model now set at US$284.79 compared with US$278.61 previously, and other price targets clustering in a wide US$260 to US$325 range. Recent commentary links these higher targets to confidence in AbbVie’s portfolio across immunology, neuroscience and oncology, while still flagging risks around specific programs and crowded positioning. As you read on, you will see how to interpret these moving targets and track the story as it...
Sat, 24 Oct 2026 00:14:01 +0000
- U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv. Patients now have the option to start SKYRIZI treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment.
Fri, 23 Oct 2026 19:33:00 +0000
- AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?
When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one sits to the edge varies far more than the yields suggest.
Fri, 23 Oct 2026 19:15:59 +0000
- Global Dental Soft Tissue Wound Care Market Size, Share, and Forecast by Product, 2026-2032 | Plug, Tape, and Foam Demand to Drive 11.8% CAGR and a $390 Million Market
The global dental soft tissue wound care market is projected to grow from nearly $180 million in 2025 to nearly $390 million by 2032, a new Research and Markets report finds, with ZimVie leading ahead of AbbVie and Henry Schein, though cost sensitivity and limited reimbursement persist.Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Dental Soft Tissue Wound Care Market Size, Share, & Trends Analysis | Global | 2026-2032 | Includes: Plug Dental Wound Care, Tape Dental Wound Care, and Foam Dental Wound
Fri, 23 Oct 2026 13:36:00 +0000
- AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fri, 23 Oct 2026 13:00:08 +0000
- AbbVie’s skin disease drug posts Phase III win as market competition heats up
This late-stage readout comes as companies explore the potential of novel mechanisms of action in HS.
Fri, 23 Oct 2026 11:39:13 +0000
- 3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.
Fri, 23 Oct 2026 11:25:00 +0000